NCT04104139 2026-04-15
TAS-102 With Concurrent Radiation for the Treatment of Untreated Resectable Stage II-III Rectal Cancer
OHSU Knight Cancer Institute
Phase 1 Active not recruiting
Clinical Trials
29 trialsNCT04920032 2026-04-13
Study of ctDNA Guided Change in Tx for Refractory Minimal Residual Disease in Colon Adenocarcinomas
University of California, Irvine
Phase 1 Recruiting
NCT04511039 2026-03-02
Trifluridine/Tipiracil and Talazoparib for the Treatment of Patients With Locally Advanced or Metastatic Colorectal or Gastroesophageal Cancer
Roswell Park Cancer Institute
Phase 1 Recruiting
NCT05029882 2025-10-29
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 as Monotherapy and in Combination With IV Bevacizumab
AbbVie
Phase 1 Active not recruiting
NCT05848739 2025-05-11
A Phase 1-2 of ST316 With Selected Advanced Unresectable and Metastatic Solid Tumors
Sapience Therapeutics
Phase 1 Recruiting
NCT04868773 2025-04-16
Study of Cabozantinib Plus TAS102 in mCRC as Salvage Therapy
University of California, Irvine
Phase 1 Active not recruiting
NCT06882915 2025-03-19
Efficacy and Safety of Trifluridine/tipiracil (TAS-102) Combined with Bevacizumab and Putalimab in the Treatment of Patients with MCRC After Cytoreductive Surgery: a Single-arm, Single-center Clinical Study
Second Affiliated Hospital, School of Medicine, Zhejiang University
Phase 1 Not yet recruiting
NCT02261532 2024-11-14
A Phase I Study of TAS-102 in Solid Tumors
Taiho Pharmaceutical Co., Ltd.
Phase 1 Completed
NCT04999761 2024-09-25
AB122 Platform Study
Taiho Pharmaceutical Co., Ltd.
Phase 1 Recruiting
NCT01867866 2024-09-05
Study Comparing the Pharmacokinetics of FTD as a Component of TAS-102 With FTD Alone
Taiho Oncology, Inc.
Phase 1 Completed
NCT01867879 2024-09-05
Study to Evaluate the Cardiac Safety of TAS-102 in Patients With Advanced Solid Tumors
Taiho Oncology, Inc.
Phase 1 Completed
NCT01874522 2024-09-05
Study Comparing the Bioavailability of TAS-102 Tablets to an Oral Solution Containing Equivalent Amounts of FTD and TPI
Taiho Oncology, Inc.
Phase 1 Completed
NCT01916447 2024-09-05
A Phase I Study of TAS-102 in Patients With Advanced Gastrointestinal Tumors.
Taiho Oncology, Inc.
Phase 1 Completed
NCT02031055 2024-09-05
Study of the Mass Balance of Oral FTD and TPI as Components of TAS-102 in Patients With Advanced Solid Tumors
Taiho Oncology, Inc.
Phase 1 Completed
NCT02301104 2024-09-05
A Phase I Study of TAS-102 in Patients With Advanced Solid Tumors With Hepatic Impairment
Taiho Oncology, Inc.
Phase 1 Completed
NCT02301117 2024-09-05
A Phase I Study of TAS-102 in Patients With Advanced Solid Tumors With Renal Impairment
Taiho Oncology, Inc.
Phase 1 Completed
NCT05130060 2024-08-14
A Vaccine (PolyPEPI1018 Vaccine) and TAS-102 for the Treatment of Metastatic Colorectal Cancer
Mayo Clinic
Phase 1 Completed
NCT04073615 2024-05-02
A Study of Rivoceranib and Trifluridine/Tipiracil for Metastatic Colorectal Cancer (mCRC)
Elevar Therapeutics
Phase 1 Terminated
NCT03317119 2024-04-08
Trametinib and Trifluridine and Tipiracil Hydrochloride in Treating Patients With Colon or Rectal Cancer That is Advanced, Metastatic, or Cannot Be Removed by Surgery
City of Hope Medical Center
Phase 1 Completed
NCT04074343 2024-02-02
TAS-102 and Irinotecan in 2L+ Gastric and Gastroesophageal Adenocarcinoma
University of California, Irvine
Phase 1 Completed
NCT04046887 2024-01-05
Study of Lonsurf in Combination With Gemcitabine and Nab-Paclitaxel in Patients With Advanced (PDAC)
Indiana University
Phase 1 Terminated
NCT03810742 2023-11-18
Nanoliposomal Irinotecan (Nal-IRI, ONIVYDE®) in Combination With TAS-102 (LONSURF®) in Refractory Solid Tumors
PharmaEngine
Phase 1 Completed
NCT03297710 2023-01-05
TAS-102 and Radiation Therapy in Treating Patients With Rectal Cancer That Is Locally Recurrent, Metastatic, or Cannot Be Removed by Surgery
Mayo Clinic
Phase 1 Completed
NCT02943733 2022-09-23
Safety of TAS-102 in Combination With Temozolomide for Metastatic Pancreatic NETs
University of Wisconsin, Madison
Phase 1 Terminated
NCT03616574 2022-09-21
First-in-human Study of CA102N Monotherapy and CA102N Combined With Trifluridine/Tipiracil (LONSURF) in Subjects With Advanced Solid Tumors
Holy Stone Healthcare Co., Ltd
Phase 1 Completed
NCT02602327 2022-08-01
Tas-102 and Radioembolization With 90Y Resin Microspheres for Chemo-refractory Colorectal Liver Metastases
University of California, San Francisco
Phase 1 Completed
NCT03974594 2022-04-19
Bioequivalence Study of Trifluridine and Tipiracil Tablets in Colorectal Cancer Patients
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 1 Completed
NCT03305913 2021-03-26
REMETY
AIO-Studien-gGmbH
Phase 1 Completed
NCT03031691 2020-08-11
A Study of Brontictuzumab With Chemotherapy for Subjects With Previously Treated Metastatic Colorectal Cancer
Mereo BioPharma
Phase 1 Completed